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journal homepage: www.urol-sci .comEditorialHypogonadism and voiding dysfunction in menMany problems may arise as men age: hypogonadism, meta-
bolic syndrome, hypertension, hyperlipidemia, low sexual drive,
poor erection, ejaculation disturbance, and ﬁnally lower urinary
tract symptom [(LUTS) including voiding difﬁculty and poor ability
to hold urine]. All of these symptoms signiﬁcantly lower the quality
of life.
In recent decades, there have been many population-based
cohort aging studies in North America and Europe.1e6 These studies
have discussed all symptoms and comorbidities of aging. The re-
sults of these studies showed that there is a close relationship be-
tween erectile dysfunction and LUTS. In the Massachusetts Male
Aging Study, erectile dysfunction (ED) was noted at 39% in 40-
year-old men, and it increased to 67% in 70-year-old men.1 In the
Baltimore Longitudinal Study 1057 patients were observed for 30
years. The results showed the prevalence of LUTS or benign pros-
tatic hyperplasia was 26% in men in their 40s, and it increased to
79% in men in their 70s.2 The Olmsted County Study followed pa-
tients for up to 12 years, and demonstrated that the prevalence of
LUTS was 26% in men in their 40s, and 46% in men in their 70s.3
The Spanish EDEM study, included 2476 men ranging in age from
25 years to 70 years. The results revealed the overall prevalence
of ED (by International Index of Erectile Function questionnaire)
was 18.9%, with a level of 8.5% in men in their 20s and 30s,
increasing to 48% in men in their 60s. Interestingly, LUTS is the
strongest risk factor of ED, the odds ratio (OR) was 2.67.4 The
German Cologne Male Survey included 5000 men, aged from 30
years to 80 years. The results showed that ED occurred in 19.2%
of the population, at 2% in men in their 40s and 53% in men in their
80s. While LUTS occurred in 72.2% in men with ED, it was seen in
37.7% of men without ED.5 The UrEpik study included 4800 men
from four countries aged from 40 years to 79 years, showing that
ED prevalence was 21.1%, and the OR of diabetes mellitus (DM) pa-
tients was 1.57, and in LUTS patients was 1.39.6 We can draw some
common facts from the epidemiological evidence. The facts are: (1)
aging is closely related to LUTS; (2) aging is also associated with
metabolic syndrome and overactivity of the autonomic nervous
system; and (3) erectile dysfunction and LUTS are tightly bound
with hypogonadism and metabolic syndrome.
In this issue, Shen and Chuang7 evaluated the prevalence and
associated factors of androgen deﬁciency (AD) in men with LUTS
in a cohort of Taiwanese men. They concluded that a considerable
portion of men comorbid with LUTS had AD. The major associated
factor of AD was a waist circumference (WC)> 90 cm, thereforeWC
measurement should be done routinely in men with LUTS.http://dx.doi.org/10.1016/j.urols.2016.05.008
1879-5226/Copyright © 2016, Taiwan Urological Association. Published by Elsevier Ta
creativecommons.org/licenses/by-nc-nd/4.0/).Physicians should pay more attention to those with WC> 90 cm
in order to identify and treat these patients earlier to improve
symptoms of LUTS and life quality.
What is the relationship between hypogonadism and LUTS?
Regarding the relationship of testosterone levels and LUTS symp-
toms, we can ﬁnd different conclusions from studies in the litera-
ture. Studies from Austria8, USA9 and Taiwan10 showed that there
are no effects present between testosterone and LUTS. However,
two recent articles from Korea reported a signiﬁcant negative cor-
relation of testosterone levels and the severity of LUTS.11,12 One
study from Japan showed dehydroepiandrosterone sulfate, not
testosterone, is associated with LUTS.13
Some studies showed that testosterone replacement therapy
(TRT) is an effective treatment for hypogonadal men with LUTS.14
The most recent randomized controlled trial (RCT) was from the
Kanazawa group, showing signiﬁcant treatment response in
relieving LUTS symptoms, maximal ﬂow rate, and voided volume.15
However, other RCTs performed in earlier years did not show pos-
itive responses.16e18
Let us examine the questions again: “Is hypogonadism a cause
for LUTS?”, and “Will TRT improve LUTS in hypogonadal men?”.
To answer these questions, we need to go back to the basics.
The embryological development of the lower urinary tract and
reproductive tract is highly controlled by sex hormones. It also con-
tributes to the proportion of collagen and smoothmuscle in the pel-
vic organs throughout the later life. The androgen and estrogen
receptors are widely distributed in urothelium, detrusor muscle,
and neurons in autonomic ganglia of the prostate plexus. The target
organs or tissues are very broad, covering the urothelial sensation,
detrusor contractility and bladder outlet status. According to the in-
ternational prostate symptom score (IPSS), LUTS includes both
voiding function and storage function. Some earlier articles dis-
cussed only the global change in IPSS, without separating these
two functions. There are seven questions present in the IPSS, Ques-
tions 1, 3, 5, and 6 representing obstructive symptoms, and Ques-
tions 2, 4, and 7 standing for storage symptoms. I have suggested
the acronyms “WISE” and “FUN” to facilitate the grouping of these
questions in 2001,19 where “WISE” means the voiding score, and
“FUN” is the storage score. Using subscore analysis, we noticed
some more interesting ﬁndings. Kim et al12 studied over 900
Korean men and showed the storage subscore is related to total
testosterone levels. More interestingly, those who had fewer noctu-
ria ( 3) had much higher testosterone levels than those who had
nocturia four times and above. The study by Amano et al20 observediwan LLC. This is an open access article under the CC BY-NC-ND license (http://
Editorial / Urological Science 27 (2016) 53e555441 Japanese hypogonadal men, in which the IPSS global score, and
both storage and voiding subscore, improved signiﬁcantly
following testosterone replacement. Recently, another observa-
tional study by Ko et al21 also showed global improvement, and
both voiding and storage subscore improvement in the Korean
cohort.
We canmodify thewell-accepted theory suggested byMcVary22
to illustrate some pathophysiological maps, in order to examine the
underlying mechanism for the improvement in LUTS after testos-
terone replacement in hypogonadal men. He proposed four the-
ories to explain the mechanism. The ﬁrst is the nitric oxide/nitric
oxide synthase (NO/NOS) theory; the second is autonomic hyperac-
tivity and metabolic syndrome hypothesis; the third is Rho-kinase
activation/endothelin pathway; and the fourth is the pelvic athero-
sclerosis theory.
For the NO/NOS theory, hypogonadism predisposes to a meta-
bolic derangement, including hyper-insulinemia, dyslipidemia,
and diabetes, which promote the reduction of NOS expression
and NO production in the prostate and bladder. Subsequently, it
will promote smooth muscle cell proliferation, and results in struc-
ture changes in the prostate. It also enhances smooth muscle
contraction in both the bladder and prostate, resulting in functional
changes. The common effects contribute to LUTS. For the auto-
nomic hyperactivity and metabolic syndrome hypothesis, hypogo-
nadism causes sarcopenia in skeletal muscle, and results in
physical inactivity. This can occur in combination with metabolic
derangements, such as insulin resistance, glucose intolerance, cen-
tral obesity and dyslipidemia, as well as aging. All increase the sym-
pathetic tone. The effects increase smooth muscle tone to cause
detrusor overactivity, and promote prostate growth to make LUTS
more severe. The Rho-kinase activation/endothelin pathway indi-
cated that the activation of Rho kinase viametabolic and autonomic
stimulation, such as noradrenaline and ET-1, results in the deactiva-
tion of the myosin-regulated light chain phosphatase, which en-
hances the contraction of the smooth muscle in the prostate.
Finally, the atherosclerosis theory is related to poor blood perfusion
to the pelvic organs, and long-term ischemia which induces the
expression of TGF-b. This promotes collagen formation and ﬁbrosis
in the bladder wall, and impairs the bladder compliance. A recent
rat model carried out in China showed the role of TGF-b in
castration-induced bladder wall ﬁbrosis.23 Control rats were
compared with castrated rats, rats which were given testosterone
replacement, and rats with anti-TGF-b antibody but without testos-
terone replacement. The results showed the recovery effects of pro-
collagen mRNA and compliance in both the testosterone
replacement group and the TGF-b antibody treated group. They
concluded that TGF-b plays an essential role in androgen
deprivation-induced bladder ﬁbrosis and dysfunction, and it might
offer a potential target for the prevention and treatment of bladder
dysfunction associated with androgen deﬁciency. A recent study in
Taiwan showed the inﬂuence of androgen receptor CAG repeat
polymorphism in men with normal testosterone levels.24 They
found men with longer CAG repeat lengths have a higher risk of
developing andropausal symptoms. This may also explain in part
why the testosterone levels are not related to LUTS symptoms in
some studies. A recent experiment using a ratmodel with hyperPRL
demonstrated the mechanism of hyperPRL-induced hypogonadism
(unpublished data). This is considered to be related to the fact that
testicular interstitial TNF-a suppresses the Leydig cells under PRL
stimulation. The hyperPRL rats showed increased ﬁbrosis and
decreased smooth muscle in the cavernosal tissue. Interestingly,
the authors found the structural change in the penis can be recov-
ered by giving testosterone replacement alone. The rats were given
testosterone enanthate, and were sacriﬁced for tissue examination
1 week after treatment. Following testosterone treatment, smoothmuscle areas increased signiﬁcantly on the penis section. The
collagen analysis showed signiﬁcant reduction in collagen III den-
sity in the treated groups. The ratio of collagen III to collagen I
reduced signiﬁcantly as well. These experiments imply that testos-
terone may act upon the regulation of mesenchymal stem cell to
differentiate into smooth muscle cells or ﬁbroblasts in other pelvic
organs or tissue.
In addition to the theories and hypotheses proposed, there are a
few new directions deserving our attention. These include the
studies on estradiol, 5-a reductase and aromatase function in the
effects of testosterone replacement, and other aspects such as the
involvement of inﬂammatory factors,11 enzyme activities,25 and
androgen receptor CAG repeat polymorphism.24
We can use Hill’s causality criteria to examine the causal effects
between two entities.22 They include strength of association, con-
sistency between studies, doseeresponse effect, temporal relation-
ship, and biological plausibility. On examining all of the evidence,
we know that LUTS and hypogonadism are highly prevalent in ag-
ingmen, and there are strong and consistent relationships between
them. But there are some other important points waiting to be
proven, for example, is the severity of hypogonadism an important
risk factor for LUTS? Is the relationship still signiﬁcant after control-
ling for other comorbidities, such asmetabolic syndrome or erectile
dysfunction? Therefore, based on Hill's causality criteria, only when
the above two questions are answered can we conclude that hypo-
gonadism is an independent risk factor for LUTS.
In conclusion, the relationship of testosterone and voiding func-
tion might be indirect and complicated, involving multiple mecha-
nism pathways and many different organs. Hypogonadism can be
connected to many pathological conditions, therefore restoration
of testosterone levels in symptomatic patients seems a cost-
effective measure. More RCTs with larger patient numbers, more
ethnicity involvement and longer follow-up are mandatory to un-
derstand the relationship between hypogonadism and LUTS.
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